Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Heavy metal or compound thereof
Patent
1995-11-03
1999-05-11
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Heavy metal or compound thereof
514274, 514283, A61K33/24
Patent
active
059026103
ABSTRACT:
This invention describes novel formulations containing a water soluble disulfide, 2,2'-dithio-bis-ethane sulfonate, with or without cis-diammine dichloro platinum present in the same formulation, wherein the parenteral or oral administration of 2,2'-dithio-bis-ethane sulfonate is used to reduce the risk or prevent or retard the development of cisplatin induced nephrotoxicity, myelosuppression, and neurotoxicity, and wherein the parenteral or oral administration of 2,2'-dithio-bis-ethane sulfonate potentiates the antitumor activity of cisplatin when treating human patients with cancer. This invention also teaches novel formulations containing 2,2'-dithio-bis-ethane sulfonate alone or in combination with cisplatin in lyophilized or dissolved in an aqueous formulations which can be administered to patients with cancer who are being treated with cisplatin. The invention also teaches methods of preparing said formulations and their use in preventing cisplatin related toxicities and potentiation of cisplatin antitumor activity.
REFERENCES:
patent: 4310515 (1982-01-01), Granatek et al.
patent: 5789000 (1998-08-01), Hausheer et al.
Leeuwenkamp et al., European Journal of Cancer, vol. 27, No. 10, pp. 1243-1247, Oct. 1991.
Shaw, I.C. and Weeks, M.S., Excretion of Disodium Bis-2- Mercaptoethanesulphonate (Dimesna) in the Urine of Volunteers after Oral Dosing; Eur J Cancer Clin Oncology 23:933-935; 1987.
Levine, Barry S., Henry, Mary C., Port, Curtis D., Richter, Ward R., and Urbanek, Mary A.; Nephrotoxic Potential of cis-Diamminedlchloroplatinum and Four Analogs in Male Fischer 344 Rats; JNCI, 67(1):210-206 Jul. 1981.
Arrick, Bradley A., et al. Glutathione Metabolism as a Determinant of Therapeutic Efficacy: A Review. Cancer Research, 44: 4224-4232, Oct. 1984.
Andrews, Paul A., et al. Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol, 19: 149-154, 1987.
Bajorin, Dean F., et al. Pharmacokinetics of cis-Diamminedichloroplatinum(II) after Administration in Hypertonic Saline. Cancer Research, 46: 5969-5972, Nov. 1986.
Borch, Richard F., et al. Effect of diethyldithiocarbamate rescue on tumor response to cisplatinum in a rat model. Proc. Natl. Acad. Sci. USA, 77: 5441-5444, Sep. 1980.
Brock, N., The Development of Mesna for the Inhibition of Urotoxic Side Effects of Cyclophosphamide, Ifosfamide, and Other Oxazaphosphorine Cytostatics. Rec. Res. Cancer Res., 74: 270-278, 1980.
Brock, Norbert, et al., Studies on the Urotoxicity of Oxazaphosphorine Cytostatics and its Prevention. Eur. J. Cancer Clin. Oncol., 17: 1155-1163, 1981.
Brock, Norbert, et al., Studies on the Urotoxicity of Oxazaphosphorine Cytostatics and its Prevention--III. Profile of Action of Sodium 2-mercaptoethane Sulfonate (Mesna). Eur. J. Cancer Clin. Oncol., 18(12): 1377-1387, 1982.
Brock, Von N., et al., Arzneim Forsch 32: 486-487 (1982).
Brock, N., et al., Pharmacokinetcis and Mechanism of Action of Detoxifying Low-Molecular-Weight Thiols. J. Cancer Res. Clin. Oncol., 108: 87-97, 1984.
Brock, Norbert, et al., The development of mesna for regional detoxification. Cancer Treatment Reviews, 10(Suppl. A): 33-43, 1983.
Burkert, Hans, et al., Clinical overview of mesna. Cancer Treatment Reviews, 10(Suppl. A): 175-181, 1983.
Burkert, H., et al., Bioavailability of Orally Administered Mesna. Arzneim.-Forsch./Drug Res., 34:(II), 1597-1600, 1984.
Campbell, A. Bruce, et al., Plasma Platinum Levels: Relationship to Cisplatin Dose and Nephrotoxicity. Cancer Treatment Reports, 67(2): 169-172, Feb. 1983.
Choie, D. David, et al., Acute and Chronic Cisplatin Nephropathy in Rats. Laboratory Investigation, 44(5): 397-402, 1981.
Daugarrd, Gedske, et al., Cisplatin nephrotoxicity A review. Cancer Chemother. Pharmacol., 25: 1-9, 1989.
DeConti, Ronald C., et al., Clinical and Pharmacological Studies with cis-Diamminedichloroplatinum(II). Cancer Research, 33: 1310-1315, Jun. 1973.
Dentino, Mariellen, et al., Long Term Effect of Cis-Diamminedichloride Platinum (CDDP) on Renal Function and Structure in Man. Cancer, 41(4): 1274-1281, Apr. 1978.
Earhart, Robert H., Instability of cis-Dichlorodiammineplatinum in Dextrose Solution. Cancer Treatment Reports, 62(7): 1105-1106, Jul. 1978.
Eastman, Alan, Gluthathione-mediated activation of anticancer platinum(IV) complexes. Biochemical Pharmacology, 36(23): 4177-4178, 1987.
Eastman, Alan, Reevaluation of Interaction of cis-Dichloro(ethylenediamine)platinum(II) with DNA. Biochemistry, 25: 3912-3915, 1986.
Glover, Donna, et al., WR-2721 and High-Dose Cisplatin: An Active Combination in the Treatment of Metastatic Melanoma. Journal of Clinical Oncology, 5(4): 574-578, Apr., 1987.
Goldstein, Robin S., et al., The Nephrotoxicity of Cisplatin. Life Sciences, 32: 685-690, 1983.
Gonzalez-Vitale, Juan C., et al., The Renal Pathology in Clinical Trials of Cis-Platinum (II)Diamminedichloride. Cancer, 39: 1362-1371, 1977.
Hayes, Daniel M., et al., High Dose Cis-Platinum Diammine Dichloride, Amelioration of Renal Toxicity by Mannitol Diuresis. Cancer, 39: 1372-1381, 1977.
Howell, Stephen B., et al., Intraperitoneal Cisplatin with Systemic Thiosulfate Protection. Annals of Internal Medicine, 97: 845-851, 1982.
Hegedus, L., et al., Chemical reactivity of cisplatin bound to human plasma proteins. Cancer Chemother. Pharmacol., 20: 211-212, 1987.
Jacobs, Charlotte, et al., Renal Handling of Cis-Diamminedichloroplatinum(II). Cancer Treatment Reports, 64(12): 1223-1226, Dec. 1980.
James, C.A., et al., Estimation of mesna and dimesna in plasma and urine by high-performance liquid chromatography with electrochemical detection. Journal of Chromatography, 382: 394-398, 1986.
Jocelyn, Biochemistry of the SH Group. Academic Press, London, New York, 1972.
Kelley, Susan L., et al., Overexpression of Metallothionein Confers Resistantce to Anticancer Drugs. Science, 241: 1813-1815, Sep. 1988.
Kempf, S.R., et al., Effective prevention of the nephrotoxicity of cis-platin (CDDP) by administration of sodium 2-mercaptoethane-sulfonate (MESNA) in rats. Br. J. Cancer, 52: 937-939, 1985.
Kociba, Richard J., et al., Acute Toxicologic and Pathologic Effects of Cis-Daimminedichloroplatinum (NSC-119875) in the Male Rat. Cancer Chemotherapy Reports, 55: 1-8, Feb. 1971.
Lemaire, Henry, et al., The Synthesis of 2-Mercaptoethane-sulfonamide. J. Org. Chem., 26: 1330-1331, Apr. 1961.
Markman, Maurie, Intraperitoneal Chemotherapy. Seminars in Oncology, 18(3): 248-254, Jun. 1991.
Leonard, B.J., et al., Antileukaemic and Nephrotoxic Properties of Platinum Compounds. Nature, 234: 43-45, Nov. 1971.
Offerman, Joop J.G., et al., Acute effects of cis-diamminedichloroplatinum (CDDP) on renal function. Cancer Chemother. Pharmacol., 12: 36-38, 1984.
Ormastad, Kari, et al., Pharmacokinetcis and Metabolism of Sodium 2-Mercaptoethanesulfonate in the Rat. Cancer Research, 43: 333-338, Jan. 1983.
Ostrow, S., et al., High-Dose Cisplatin Therapy Using Mannitol Versus furosemide Diuresis: Comparative Pharmacokinetics and Toxicity. Cancer Treatment Reports, 65: 73-78, 1981.
Ozols, Robert F., et al., High-Dose Cisplatin in Hypertonic Saline. Annal s of Internal Medicine, 100: 19-24, 1984.
Pfeifle, Craig E., et al., High-Dose Cisplatin with Sodium Thiosulfate Protection. Journal of Clinical Oncology, 3(2): 237-244, Feb. 1985.
Pinto, Ann L., et al., Binding of the Antitumor Drug cis-Diamminedichloroplatinum(II) (Cisplatin) to DNA. Biochimica et Biophysica Acta., 780: 167-180, 1985.
Pohl, Von J., et al., Meth. Find. Clin. Pharmacol. 3(Supp. 1): 95-101, 1981.
Perry, M.C., The Chemotherapy Source Book, Williams and Wilkins, 1172 pp., 1992.
Reed, Eddie, et al., Platinum Analogues in Cancer Chemotherapy, Principles and Practice, 465-490, 1990.
Rosenberg, Barnett, et al., Platinum Compounds: a New Class of Potent Antitumor Agents. Nature, 222: 385-386, Apr. 1969.
Rozencweig, Marcel, et al., Cis-diamminedichloroplatinum (II) A New Anticancer Drug. Annals of Internal Medicine, 86: 803-812, 1977.
Safirstein, Robert, et al., Cisplatin Nephrotoxicity. American Journal of Kidney Diseases, 8(5): 356-367, Nov. 1986.
Sidau, Beate, et al
Haridas Kochat
Hausheer Frederick Herman
Murali Dhanabalan
Peddaiahgari Seetharamulu
Reddy Dasharatha Gauravaram
BioNumerik Pharmaceuticals, Inc.
Dodd Thomas J.
Raymond Richard L.
LandOfFree
Formulations and methods of use of 2,2'-dithio-bis-ethane sulfon does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Formulations and methods of use of 2,2'-dithio-bis-ethane sulfon, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulations and methods of use of 2,2'-dithio-bis-ethane sulfon will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-244578